Lexicon Pharmaceuticals - XERMELO - Ownership and Business Overview

Life ScienceCompany

Lexicon Pharmaceuticals - XERMELO Ownership

Who owns Lexicon Pharmaceuticals - XERMELO?

Lexicon Pharmaceuticals - XERMELO is owned by TerSera Therapeutics. It was acquired on July 30, 2020.

Lexicon Pharmaceuticals - XERMELO Business Overview

Where is Lexicon Pharmaceuticals - XERMELO headquartered?

Lexicon Pharmaceuticals - XERMELO is headquartered in The Woodlands, Texas.

What sector is Lexicon Pharmaceuticals - XERMELO in?

Lexicon Pharmaceuticals - XERMELO is a life science company.

Life Science M&A Summary in 2020

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2020. The largest life science acquisition in 2020 was Alexion Pharmaceuticals - which was acquired by AstraZeneca for $39.0B.

Join Mergr to view all 290 acquisitions of life science companies in 2020, including 23 acquisitions by private equity firms, and 267 by strategics.

Lexicon Pharmaceuticals, Inc. - XERMELO

The Woodlands, Texas
United States,
www.xermelo.com

Lexicon Pharmaceuticals's XERMELO is an approved oral therapy for carcinoid syndrome diarrhea. It targets tryptophan hydroxylase, an enzyme that mediates the excess serotonin production within metastatic neuroendocrine tumor (mNET) cells. XERMELO is approved in the United States, the European Union, and certain additional countries for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. Carcinoid syndrome is a rare condition that occurs in patients living with mNETs and is characterized by frequent and debilitating diarrhea. XERMELO targets the overproduction of serotonin inside mNET cells, providing an additional treatment option for patients suffering from carcinoid syndrome diarrhea.


 Subscribe to unlock this and 208,055
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 201K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.